UBS raised the firm’s price target on Delek US (DK) to $42 from $31 and keeps a Neutral rating on the shares. Delek US is one of the biggest beneficiaries of Small Refinery Exemptions, and the company should continue to get full exemptions for at least two refining assets under the Trump administration, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DK:
- Delek US price target raised to $40 from $34 at Morgan Stanley
- Delek US price target raised to $47 from $39 at Piper Sandler
- Delek US price target raised to $36 from $28 at TD Cowen
- Delek US price target raised to $45 from $37 at Mizuho
- Delek US Holdings: Hold Rating Maintained Amid Improved Earnings and Future Uncertainties